Trial Profile
A Randomized, Double-blind, Placebo-controlled Phase 1/2 Study of OTO-413 Given as a Single Intratympanic Injection in Subjects With Speech-in-noise Hearing Impairment
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 01 Nov 2022
Price :
$35
*
At a glance
- Drugs OTO-413 (Primary)
- Indications Sensorineural hearing loss
- Focus Adverse reactions; First in man
- Sponsors Otonomy [CEASED]
- 25 Oct 2022 Status changed from active, no longer recruiting to completed.
- 25 Jul 2022 According to an Otonomy media release, the company expects to announce top-line from this study in the fourth quarter of 2022.
- 28 Feb 2022 According to an Otonomy media release, the company expects to announce top-line results for OTO-413 higher dose evaluation in second half of 2022.